After a solid decade of optimism that the city and surrounding region were creating a new economy that would support a growing population, one based on "eds and meds" instead of steel, the population turnaround has proved illusory and building — both of physical structures and of businesses — has slowed.

Pittsburgh’s geographic and institutional resources, from enormous brownfield sites to world-class universities, remain among the strongest anywhere in the country. Regions need their institutions, public and private, to work together to identify gaps in the economic and academic ecosystem, and to fill those gaps in order to build and keep economic growth right here.

One example of this quietly happening in Pittsburgh is BioForge, a biomanufacturing design and research organization in Hazelwood Green sponsored by the University of Pittsburgh. BioForge received a $100 million boost in 2021 from the Richard King Mellon Foundation, allowing the project to begin going from concept to reality.

The nonprofit organization is a bridge between academic research and commercially viable life-saving therapies. At any given time, dozens of academic research projects are ongoing at Pitt and CMU. The findings of many of these projects could be applied to create new medicines and treatments.

Advertise with us

The trouble is that a proof of concept in the lab and a therapy that can be effectively mass produced and delivered to patients are two very different things. Despite their massive potential, the cost in time and money — and the likelihood that most lab breakthroughs won’t make it to market — means for-profit corporations are unlikely to take them on.

Take CAR-T therapies, in which the patient’s own immune cells (T-cells) are extracted, reprogrammed to attack cancer cells, and reinserted into the body. It’s a massively expensive — up to half a million dollars per treatment — and time-consuming process. While CAR-T treatment has shown promise, it’s very hard to scale.

That’s where BioForge steps in. As a nonprofit, it can work with speculative advancements that could make CAR-T more accessible, refining them for scalability and marketability. Not every advancement will make the cut — BioForge will cut loose projects that aren’t showing promise in order to focus on those that are — but they’ll give new tech chances the projects wouldn’t get in the for-profit sector.

This completes the chain from the lab to the marketplace — and potentially keeps it all right here in southwest Pennsylvania. It will make Pitt and CMU more attractive to ambitious researchers and could lead to new companies being founded in our region that wouldn’t have been if this essential link weren’t located here.

BioForge is a reminder of the opportunities for growth that are ongoing in Pittsburgh, even as Allegheny County recorded one of the worst population declines in the country last year.

And its collaborative creation, between people who saw a need and found a way to provide it, offer a model for the city’s government, foundation, nonprofit and corporate institutions to work together to make Pittsburgh work again.